MYC and neoplasm: Further, IF and confocal analyses revealed further reduction of cell proliferation marker Ki-67 and tumor angiogenesis marker CD31 in tumor tissues upon combined treatment with PS-MYC and PS-Gp130 peptides (Figure 9C).